Table 2. Results of statistical analysis.
| Contrast | Stable disease (median & iqr) | Early progression (median & iqr) |
p-val. (U-test) |
AUC (95% CI) |
p-val. (AUC) | Best cut-off | Sensitivity (95% CI) |
Specificity (95% CI) |
|---|---|---|---|---|---|---|---|---|
| NOE-LD |
11.66 (11.18–12.31) |
10.37 (10.31 – 10.48) |
0.0001 |
0.98 (0.92 – 1.00) |
0.0005 | 10.89 |
0.91 (0.82 – 1.00) |
1.00 (0.88 – 1.00) |
| NOE-AREX | 9.91 (9.25 – 11.90) |
8.95 (8.25 – 9.87) |
0.1288 | 0.72 (0.48 – 0.95) |
0.1167 | 9.81 | 0.64 (0.27 – 1.00) |
0.75 (0.38 – 1.00) |
| MTR-asym (NOEw) |
−5.71 (−6.41 – − 4.82) |
-4.52 (−4.90 – 3.39) |
0.0186 |
0.83 (0.64 – 1.00) |
0.0166 | −5.23 |
0.73 (0.45 – 1.00) |
1.00 (0.50 – 1.00) |
| APT-LD | 5.28 (5.12 – 5.39) |
5.36 (4.90 – 6.06) |
1.0000 | 0.50 (0.18 – 0.82) |
1.0000 | 5.92 | 0.91 (0.18 – 1.00) |
0.38 (0.13 – 1.00) |
| APT-AREX | 4.22 (3.85 – 4.76) |
4.73 (4.27 – 4.80) |
0.3421 | 0.64 (0.37 – 0.90) |
0.3218 | 4.3 | 0.64 (0.18 – 0.91) |
0.75 (0.50 -1.00) |
| dns-APT |
2.14 (1.92 – 2.28) |
2.71 (2.56 – 3.09) |
0.0328 |
0.80 (0.57 – 1.00) |
0.0318 | 2.29 |
0.82 (0.54 – 1.00) |
0.88 (0.63 – 1.00) |
| T2w TSE | 554 (485 – 666) |
563 (444 – 632) |
0.6784 | 0.56 (0.17 – 0.71) |
0.6434 | 595 | 0.58 (0.33 – 0.83) |
0.50 (0.13 – 0.88) |
| ADC (3 Tesla) |
10.72 (9.92 – 11.63) |
10.35 (10.17 – 10.86) |
0.7168 | 0.56 (0.27 – 0.85) |
0.6797 | 10.53 | 0.64 (0.09 – 0.91) |
0.75 (0.38 – 1.00) |
| Age | 60 years (51 – 70 years) |
60 years (54 – 70 years) |
0.6710 | 0.56 (0.29 – 0.83) |
0.6434 | 52.5 | 0.88 (0.63 – 1.00) |
0.42 (0.17 – 0.67) |
(iqr = interquartile range, AUC = area under curve, CI = confidence interval).